BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 35467477)

  • 21. Circular RNA circ-RNF121 contributes to cisplatin (DDP) resistance of non-small-cell lung cancer cells by regulating the miR-646/SOX4 axis.
    Liu Y; Zhai R; Hu S; Liu J
    Anticancer Drugs; 2022 Jan; 33(1):e186-e197. PubMed ID: 34387608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
    Pang J; Ye L; Zhao D; Zhao D; Chen Q
    Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CircRNA_100565 contributes to cisplatin resistance of NSCLC cells by regulating proliferation, apoptosis and autophagy via miR-337-3p/ADAM28 axis.
    Zhong Y; Lin H; Li Q; Liu C; Shen J
    Cancer Biomark; 2021; 30(2):261-273. PubMed ID: 33682697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5).
    Wei D; Zeng J; Rong F; Xu Y; Wei R; Zou C
    Bioengineered; 2022 Mar; 13(3):5126-5140. PubMed ID: 35170372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exosome-Derived Circ-PVT1 Contributes to Cisplatin Resistance by Regulating Autophagy, Invasion, and Apoptosis Via miR-30a-5p/YAP1 Axis in Gastric Cancer Cells.
    Yao W; Guo P; Mu Q; Wang Y
    Cancer Biother Radiopharm; 2021 May; 36(4):347-359. PubMed ID: 32799541
    [No Abstract]   [Full Text] [Related]  

  • 27. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
    Fu J; Cai H; Wu Y; Fang S; Wang D
    Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anesthetic propofol enhances cisplatin-sensitivity of non-small cell lung cancer cells through N6-methyladenosine-dependently regulating the miR-486-5p/RAP1-NF-κB axis.
    Ling Q; Wu S; Liao X; Liu C; Chen Y
    BMC Cancer; 2022 Jul; 22(1):765. PubMed ID: 35836137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p.
    Li M; Wang Q; Zhang X; Yan N; Li X
    Cell Cycle; 2021 Jul; 20(13):1279-1294. PubMed ID: 34097560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circular RNA PRMT5 knockdown enhances cisplatin sensitivity and immune response in non-small cell lung cancer by regulating miR-138-5p/MYH9 axis.
    Xu Y; Zhao R; Wang H; Jiang J; Wang Z; Wang J; Zhang W; Li M
    J BUON; 2021; 26(5):1850-1861. PubMed ID: 34761592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
    Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
    Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
    Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J
    Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. m
    Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
    J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circ_0004015 silencing represses cisplatin chemoresistance and tumor progression by reducing KLF8 in a miR-198-dependent manner in non-small cell lung cancer.
    Li Y; Yang X; Xiong X
    Genomics; 2022 Mar; 114(2):110294. PubMed ID: 35134495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
    Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
    Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/β-catenin pathway.
    Shi SL; Zhang ZH
    Neoplasma; 2019 Sep; 66(5):756-765. PubMed ID: 31288529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-106a-5p alleviated the resistance of cisplatin in lung cancer cells by targeting Jumonji domain containing 6.
    Ge X; Jiang Y; Hu X; Yu X
    Transpl Immunol; 2021 Dec; 69():101478. PubMed ID: 34607003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circ_0048856 competes with ABCC1 for miR-193a-5p/miR-98-5p binding sites to promote the cisplatin resistance and tumorigenesis in lung cancer.
    Liu L; Zhang Q; Peng H
    J Chemother; 2023 Feb; 35(1):39-52. PubMed ID: 35289739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.